PORTFOLIO

Avigen was a NASDAQ-traded biopharmaceutical company focused on developing and commercializing unique small molecule therapeutics to treat serious neurological disorders, including neuropathic pain and neuromuscular spasm and spasticity. Avigen was developing AV650 for spasticity and neuromuscular spasm and AV411 for neuropathic pain as well as opioid withdrawal and addiction. Additionally, the company was advancing toward clinical trials AV513, a novel therapy for the treatment of multiple bleeding disorders, including hemophilia A and B when it was acquired by MediciNova in 2009.

Seed-One Managing Partner Jeff Wolf co-founded Avigen.

Cardiac Dimensions is developing novel interventional tools for the treatment of mitral valve regurgitation associated with dilated cardiomyopathy in the setting of congestive heart failure. CHF is a life-threatening condition afflicting nearly 5 million Americans and responsible for 2.5 million hospital admissions each year. Given their poor state of health, CHF patients are rarely candidates for conventional surgical procedures that could extend and improve their lives. Cardiac Dimensions is developing a novel, minimally invasive therapy for mitral regurgitation as an alternative to surgery, thus significantly expanding the pool of CHF patients that can be helped.

Seed-One Managing Partner Scott Wolf founded Cardiac Dimensions.

Elusys Therapeutics, a New Jersey-based biopharmaceutical company, is focused on the development of first-in-class antibody therapies for the treatment of infectious disease. The Company’s most advanced product, Anthim, is a therapeutic for the treatment of Anthrax, a category A biowarfare agent. In animal efficacy studies, a low dose of Anthim provided significant protection from death even when given 48 hours after anthrax exposure. Anthim clinical safety studies for Anthim will begin in early 2005. In the commercial sector, Elusys is applying its Heteropolymer technology in the development of a treatment for Staph aureus infections. The Anti-Staph A Heteropolymer has demonstrated significant efficacy in the prophylaxis and treatment of Saureus in animal models. The Company intends to apply the Heteropolymer technology to the development of similar antibody-based therapies to treat other bacterial and viral infections.

Seed-One Managing Partner Jeff Wolf co-founded Elusys and served as its Chairman and CEO.

EndoGastric Solutions, Inc. designs, manufactures and markets endoluminal procedures for the treatment of upper gastrointestinal diseases, gastroesophageal reflux diseases, and obesity problems. Its products include EsophyX System with Serofuse Fastener for use in endoluminal, transoral tissue approximation, thickness plication and ligation in the GI tract, and is indicated for the treatment of symptomatic chronic gastroesophageal reflux disease in patients who require and respond to pharmacological therapy; and StomaphyX, a single-use device for use in endoluminal trans-oral tissue approximation and ligation in the GI tract. The company offers its products through distributors in Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Luxembourg, Mexico, the Netherlands, South Africa, Spain, Portugal, the United Kingdom, the United States, the Czech Republic, Finland, Hungary, Poland, Slovenia, and Sweden. The company is headquartered in Redmond, Washington.

Seed-One Managing Partner Scott Wolf founded EndoGastric Solutions.

GenerationOne leverages advanced mobile technologies and clinical decision support to provide an end-to-end solution that provides multi-directional communications and timely access to critical information that enables physicians, caregivers, families and patients to collaborate for better health management. The company’s proprietary wireless health management system is a flexible suite of components, including the GenerationOne mobile phone, which is optimized for delivery of health information, a web-based control center and notification, voice and data services that can be customized to monitor a wide range of disease and wellness conditions. This allows providers, payers, employers and others responsible for managing the delivery and cost of healthcare to work with patients and consumers to integrate interactive, targeted health management tools and information services into their daily routines. By delivering real-time interventions and always-on decision support, GenerationOne’s mobile healthcare solution results in more efficient healthcare delivery and improved patient outcomes.

Seed-One Managing Partner Jeff Wolf founded GenerationOne and served as its Chairman and CEO.

Heat Biologics (NASDAQ:HTBX) is an immuno-oncology company focused on developing drugs its novel, “off-the-shelf” ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to “pump out” a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called “gp96” to educate and activate a cancer patient’s immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial of its viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer as well as a Phase 2 trial with its vesigenurtacel-L (HS-410) in patients with non-muscle invasive bladder cancer.

Seed-One Managing Partner Jeff Wolf founded Heat Biologics and serves as its Chairman and CEO.

Primaeva Medical is developing devices for dermatologists, plastic surgeons and other cosmetic/aesthetic physicians.

Primaeva Medical is dedicated to providing the aesthetic physician superior new tools for Restoring Youth for their patients who want to reverse the signs of aging. In 2009 Primaeva introduced a groundbreaking fractional radiofrequency system designed for the predictable treatment of aging skin. Primaeva was acquired by Syneron (NASDAQ: ELOS) in 2009.

Seed-One Managing Partner Scott Wolf founded Primaeva Medical.

TyRx Pharma, Inc. was focused on developing implantable combination drugdevice products utilizing novel biomaterials. Additionally, TyRx has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of post surgical nosocomial infection. TyRx was deploying its capabilities across a broad range of combination implantable medical-pharmaceutical devices. TyRx was acquired by Medtronic in 2011.

Seed-One Managing Partner Jeff Wolf co-founded Tyrx and served as its Chairman.

ZELTIQ Aesthetics is winning the battle of the bulge. The company’s CoolSculpting device offers a non-invasive treatment as an alternative to liposuction to knock out fat cells. The treatment uses controlled cooling to reduce the temperature of fat cells and melt fat without causing scar tissue or skin damage. ZELTIQ Aesthetics received FDA approval in 2010 to use the CoolSculpting device on targeted areas of the torso, aka the “love handles,” but it is also used in about 45 other international markets. The CoolSculpting system is sold to dermatologists, plastic surgeons, and aesthetic specialists such as medical spas. ZELTIQ Aesthetics completed a $115 million initial public offering in July 2011.

Seed-One Managing Partner Scott Wolf founded Zeltiq and served as its CEO.